David Schenkein is passing the reins at Agios to Jackie Fouse after a star-making 10-year run
David Schenkein’s long run as Agios CEO — growing the company from his legendary blank sheet of paper to a high profile public biotech with close to 500 staffers, two approved drugs on the market and more advancing in the pipeline — is coming to an end.
In 5 months Schenkein is passing the reins of the Cambridge, MA-based company to Jackie Fouse, the ex-Celgene exec who went on to run one of Vivek Ramaswamy’s biotechs for a short stint. After Fouse jumped on the Agios board late last year, he says, the regular discussions with the board about a transition plan began to gel. And “it became clear that Jackie had an interest in that role.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.